Vaccine manufacturers

  • 文章类型: Journal Article
    目前尚不清楚中国父母对疫苗的偏好是什么,这些疫苗可能会被添加到未来的免疫计划中。这项研究的目的是评估中国父母对疫苗属性的偏好。我们在上海免疫诊所调查了年龄≤3个月的幼儿的父母,中国,在2017年。我们使用离散选择实验(DCE)向父母提供两个假设的疫苗概况之间的选择,这些疫苗使用以下属性进行描述:成本,副作用的风险,疫苗制造商的位置,疫苗测试,疫苗有效性,疾病的严重程度,疾病患病率。偏好效用的逻辑回归输出估计。总的来说,599名护理人员完成了DCE。父母表示对疫苗的偏好较低,其中30%的机会发烧为不良事件,而10%的机会(OR:0.53,95%CI:0.44,0.64),对于疫苗,只有85%有效vs95%有效(OR:0.55,95%CI:0.48,0.62),与国产疫苗相比,进口疫苗(OR:0.74,95%CI:0.60,0.92)和未在中国儿童中进行测试的疫苗(OR:0.45,95%CI:0.37,0.53)。较富裕的群体更喜欢更昂贵的疫苗,而较不富裕的群体则没有表达基于成本的偏好。在中国推广疫苗应侧重于父母陈述的偏好,其中包括过去在中国儿童中进行的测试-也就是说,事实上,中国所有许可疫苗的要求。关于这些试验的信息可以强调不良事件的低风险和高有效性。
    It is not clear what kind of preferences parents in China would have for vaccines that could be added to a future immunization schedule. This study\'s aim was to assess Chinese parents\' preferences for attributes of vaccines. We surveyed parents of young infants ≤3 months of age at immunization clinics in Shanghai, China, in 2017. We used a discrete choice experiment (DCE) to present parents with choices between two hypothetical profiles of vaccines which were described using the following attributes: cost, risk of side effect, location of vaccine manufacturer, vaccine testing, vaccine effectiveness, severity of disease, disease prevalence. A logistic regression output estimates of preference utilities. In total, 599 caregivers completed the DCE. Parents expressed lower preference for vaccines with a 30% chance of fever as an adverse event vs a 10% chance (OR: 0.53, 95% CI: 0.44, 0.64), for vaccines only 85% effective vs those 95% effective (OR: 0.55, 95% CI: 0.48, 0.62), and for imported vaccines (OR: 0.74, 95% CI: 0.60, 0.92) and those not tested in Chinese children (OR: 0.45, 95% CI: 0.37, 0.53) compared to domestic vaccines. More affluent groups preferred more expensive vaccines whereas less affluent groups did not express cost-based preferences. Promotion of vaccines in China should focus on parents\' stated preferences, which include past testing done in Chinese children - which is, in fact, required of all licensed vaccines in China. Information about these trials could emphasize low risk of adverse events and high effectiveness.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Sci-hub)

公众号